BUCHANG PHARMA: Wholly-owned subsidiary obtains drug registration certificate for Oseltamivir Phosphate Capsules

Zhitong
2025.08.28 08:50

BUCHANG PHARMA announced that its wholly-owned subsidiary, Shaanxi Buchang High-tech Pharmaceutical Co., Ltd., recently received the Drug Registration Certificate for Oseltamivir Phosphate Capsules issued by the National Medical Products Administration. This drug is mainly used for the treatment of influenza A and B in adults and children aged 1 year and older, as well as for the prevention of influenza A and B in adults and adolescents aged 13 years and older. The annual sales of physical pharmacies in Chinese cities from 2022 to 2024 are projected to be 152 million yuan, 824 million yuan, and 776 million yuan, respectively. As of the announcement date, the company has invested approximately 12.9612 million yuan in research and development expenses for this project

Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2026 Longbridge｜Disclaimer